Canary Bio Recruits Talent from Multinational Pharma BMS... "Full-Scale Commercialization Launch"

[Asia Economy Reporter Jang Hyowon] Canaria Bio announced on the 24th that it has officially started commercialization by recruiting Dr. Sri Jada, formerly of multinational pharmaceutical company BMS, as Head of Medical Affair.

Dr. Jada served as the head of the Medical Affair team, a dedicated medical organization, at multinational pharmaceutical companies BMS, MSD, Merck, and AstraZeneca, overseeing the launch of several products including Nivolumab. Canaria Bio is establishing a commercialization organization as the global Phase 3 clinical trial patient recruitment enters its final stage.

The function of the Medical Affair team is focused on external communication, including internal communication between R&D and commercialization departments, external communication between the company and outside stakeholders, marketing clinical strategy development, expert and public education, and collaboration with patient associations.

Dr. Jada led joint clinical research between BMS and Canaria Bio. He conducted a combination therapy clinical trial of BMS’s immune checkpoint inhibitor Nivolumab and Canaria Bio’s Oregovomab.

Dr. Jada said, “Oregovomab showed encouraging results by extending progression-free survival (PFS) by 30 months in Phase 2 clinical trials. While conducting joint research with Canaria Bio during my tenure at BMS, I saw the potential of Oregovomab and decided to join Canaria Bio.”

This content was produced with the assistance of AI translation services.